Corbus Pharmaceuticals Holdings, Inc. CRBP
At closeNov 6, 2026, 4:46 AM EST
Pre-market · Nov 6, 4:46 AM ET
- YTD
- -64.86%
- 1 year
- -73.76%
- Market cap
- 55.32M
- EPS (ttm)
- -6.11
- Shares out
- 12.18M
- Forward P/E
- -2.51
- YTD return
- -64.86%
- 1-year return
- -73.76%
- Volume
- 1.36M
- Avg volume
- 1.05M
- Open
- 3.57
- Previous close
- 3.57
- Day's range
- 2.81 – 3.57
- 52-week range
- 2.81 – 12.88
- Beta
- 2.56
- Analysts
- Strong Buy
- Price target
- 56.78 (+1885.2%)
YTD -5.01 (-63.66%)
Key statistics
- Enterprise value
- 2.58M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.40M
- Total cash
- 159.36M
- Total debt
- 3.61M
- Return on equity
- -51.32%
- Short % of float
- 24.72%
- 50-day average
- 16.87
- 200-day average
- 37.65
Analyst view
Consensus: strong buy
- Target (low)
- 35.00
- Target (mean)
- 56.78
- Target (high)
- 75.00
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.99 | -1.15 | -0.16 | -16.16% |
| Aug 6, 2024 | Jun 1, 2024 | -1.16 | -0.90 | +0.26 | +22.41% |
| May 7, 2024 | Mar 1, 2024 | -1.09 | -0.83 | +0.26 | +23.85% |
| Mar 12, 2024 | Dec 1, 2023 | -2.36 | -1.81 | +0.55 | +23.31% |
| Nov 7, 2023 | Sep 1, 2023 | -2.06 | -2.27 | -0.21 | -10.19% |
| Aug 8, 2023 | Jun 1, 2023 | -3.10 | -2.05 | +1.05 | +33.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Piper Sandler | init | — | Overweight |
| Aug 7, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 7, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Jun 26, 2024 | B. Riley Securities | init | — | Buy |
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- corbuspharma.com
News
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November 
Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target 
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Market-Moving News for September 14th 
Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity 
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Friday's After-Market Session 
Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT
Your note
Sign in to keep a note on CRBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMEYER ANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
| CATLIN AVERY W | Director | Stock Award(Grant) | May 29, 2024 | 4,350 |
| COHEN YUVAL | Chief Executive Officer | Sale | Jun 17, 2024 | 77,221 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 19, 2024 | 0 |
| HOLMER ALAN F | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 5,829 |
| JACQUES RACHELLE SUZANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 19.50% | 2,375,000 | 31.25M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 9.15% | 1,115,000 | 14.67M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 7.49% | 912,552 | 12.01M | Sep 29, 2024 |
| Blackrock Inc. | 6.59% | 802,721 | 10.56M | Sep 29, 2024 |
| Vanguard Group Inc | 5.30% | 645,650 | 8.50M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.93% | 600,000 | 7.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.21% | 391,276 | 5.15M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.70% | 329,220 | 4.33M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.21% | 269,243 | 3.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 169,055 | 2.22M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.85% | 104,055 | 1.37M | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 68,254 | 898.22K | Oct 30, 2024 |